MedTrace Logo

Paclitaxel and Cisplatin for Thymic Neoplasm

NCT00818090 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2013-04-12

No results posted yet for this study

Summary

To assess the efficacy and safety of the regimen in previously untreated, unresectable invasive thymoma or thymic carcinoma

Conditions

  • Thymoma
  • Thymic Carcinoma

Interventions

DRUG

paclitaxel and cisplatin

paclitaxel and cisplatin every 3 weeks

Sponsors & Collaborators

  • Korean Cancer Study Group

    lead OTHER

Principal Investigators

  • Dae Seog Heo, MD, PhD · Seoul National University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00818090 on ClinicalTrials.gov